A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

The present trial is an open, single-arm phase I clinical study aimed at assessing the safety, tolerability, viral distribution and shedding patterns, pharmacodynamics, immunogenicity, and antitumor efficacy of GC001 oncolytic virus injection in patients with advanced solid tumors following a single administration.

Trial Details

NCT ID

NCT06508307

Phase

PHASE1

Sponsor

GONGCHU Biotechnology Co., Ltd

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors

Locations (sample)

Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

To be eligible for participation in this study, individuals must meet the following criteria:
Fully comprehend the purpose, nature, methods, and potential adverse effects of the trial, volunteer as a participant, and provide informed consent…
Be male or female patients aged 18 to 75 years (including those with borderline age values).
Patients with advanced solid tumors, including but not limited to: colorectal cancer, lung cancer, ovarian cancer, cervical cancer, etc., that have…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →